A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Vaccine

• Publication date

  2007-07-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2007.04.081PMID 17548137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacillus anthracis Edema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens1

  2006cited by this paper
• α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor1

  2005cited by this paper
• Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.

  2005cited by this paper
• Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

  2005cited by this paper
• Enterotoxin-Based Mucosal Adjuvants Alter Antigen Trafficking and Induce Inflammatory Responses in the Nasal Tract

  2005cited by this paper
• Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.

  2004cited by this paper
• Influenza-associated hospitalizations in the United States.

  2004cited by this paper
• Practical Synthesis of KRN7000 from Phytosphingosine

  2004cited by this paper
• Current status of live attenuated influenza virus vaccine in the US.

  2004cited by this paper
• The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

  2003cited by this paper
• The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response

  2003cited by this paper
• Role of the Polymeric Ig Receptor in Mucosal B Cell Homeostasis1

  2003cited by this paper
• NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo 1

  2003cited by this paper
• Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein

  2003cited by this paper
• Immunotherapy with ligands of natural killer T cells.

  2002cited by this paper
• Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).

  2002cited by this paper
• Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa.

  2002cited by this paper
• Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen

  2001cited by this paper
• Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene.

  2001cited by this paper
• Emergence of H3N2 reassortant influenza A viruses in North American pigs.

  2000cited by this paper
• alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.

  2000cited by this paper
• Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo

  2000cited by this paper
• α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria.

  2000cited by this paper
• The impact of influenza epidemics on hospitalizations.

  2000cited by this paper
• Inhibition of T Helper Cell Type 2 Cell Differentiation and Immunoglobulin E Response by Ligand-Activated Vα14 Natural Killer T Cells

  1999cited by this paper
• Zonula Occludens Toxin Is a Powerful Mucosal Adjuvant for Intranasally Delivered Antigens

  1999cited by this paper
• Immunization with α‐galactosylceramide polarizes CD1‐reactive NK T cells towards Th2 cytokine synthesis

  1999cited by this paper
• Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.

  1999cited by this paper
• Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.

  1999cited by this paper
• CD1-mediated immune responses to glycolipids.

  1999cited by this paper
• Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000.

  1998cited by this paper
• Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

  1998cited by this paper
• CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

  1997cited by this paper
• Nasal delivery of vaccines.

  1996cited by this paper
• Interspecies transmission of influenza viruses.

  1995cited by this paper
• Impaired Antibody Response to Influenza Vaccine in Institutionalized Elderly a

  1994cited by this paper
• Impaired antibody response to influenza vaccine in institutionalized elderly.

  1994cited by this paper
• Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones.

  1982cited by this paper
• Lack of age-associated immune dysfunction in mucosal-associated lymph nodes.

  1981cited by this paper
• Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses

  1975cited by this paper
• Plaque assay and primary isolation of influenza a viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin

  1975cited by this paper

• Glycolipid antigen recognition by invariant natural killer T cells and its role in homeostasis and antimicrobial responses

  2024cites this paper
• Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens

  2023cites this paper
• Intranasal COVID-19 vaccines: From bench to bed

  2022cites this paper
• Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs

  2022cites this paper
• A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine

  2022cites this paper
• Encapsulation of MERS antigen into α-GalCer-bearing-liposomes elicits stronger effector and memory immune responses in immunocompetent and leukopenic mice

  2022cites this paper
• The interaction between iNKT cells and B cells

  2021cites this paper
• Ceramide and Related Molecules in Viral Infections

  2021cites this paper
• Invariant natural killer T cells balance B cell immunity

  2021cites this paper
• Harnessing NKT cells for vaccination

  2021cites this paper
• Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells

  2020cites this paper
• Role of γδ T cells in controlling viral infections with a focus on influenza virus: implications for designing novel therapeutic approaches

  2020cites this paper
• The Mucosal Immune System: An Outlook for Nanovaccines Development

  2019cites this paper
• A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice

  2019influential citation
• Infection Prevention: Oil- and Lipid-Containing Products in Vaccinology

  2018cites this paper
• Sphingolipids in early viral replication and innate immune activation

  2018cites this paper
• Activation and Regulation of B Cell Responses by Invariant Natural Killer T Cells

  2018cites this paper
• Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control

  2018cites this paper
• Innate and adaptive T cells in influenza disease

  2018cites this paper
• This information is current as Vaccine Adjuvants and Delivery Systems Inducing Mucosal IgA : A Challenge for

  2017cites this paper
• Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems

  2017cites this paper
• Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective

  2017cites this paper
• Contribution of innate immune cells to pathogenesis of severe influenza virus infection.

  2017cites this paper
• Augmenting Influenza-Specific T Cell Memory Generation with a Natural Killer T Cell-Dependent Glycolipid-Peptide Vaccine.

  2017cites this paper
• Glycolipid activators of invariant NKT cells as vaccine adjuvants

  2016cites this paper
• Engaging Natural Killer T Cells as ‘Universal Helpers’ for Vaccination

  2016cites this paper
• Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents

  2016cites this paper
• α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant

  2016cites this paper
• Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine

  2016cites this paper
• The Role of Invariant NKT Cells in Immunity

  2016cites this paper
• mTOR Regulation of Lymphoid Cells in Immunity to Pathogens

  2016cites this paper
• The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8+ T Cell Generation

  2015cites this paper
• Regulation of NKT Cell Localization in Homeostasis and Infection

  2015cites this paper
• In Vivo Targeting of Dendritic Cells with Artificial Adjuvant Vector Cells (aAVC) as a Novel Cancer Immunotherapy

  2015cites this paper
• Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.

  2015cites this paper
• iNKT Cells and Their Potential Lipid Ligands during Viral Infection

  2015cites this paper
• Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir

  2015cites this paper
• Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant

  2014cites this paper
• Biology of CD1- and MR1-restricted T cells.

  2014cites this paper
• Mucosal vaccines

  2014cites this paper
• Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs.

  2014cites this paper
• Optimizing NKT cell ligands as vaccine adjuvants.

  2014cites this paper
• Characterizing immunogenetic factors associated with influenza cross-reactive responses and disease severity

  2014cites this paper
• iNKT‐cell help to B cells: A cooperative job between innate and adaptive immune responses

  2014cites this paper
• cell help , vaccines , T follicular helper cells

  2014cites this paper
• The role of invariant natural killer T cells in microbial immunity

  2013cites this paper
• Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo.

  2013cites this paper
• In‐vivo stimulation of macaque natural killer T cells with α‐galactosylceramide

  2013cites this paper
• TLR 1-induced chemokine production is critical for mucosal immunity against Yersinia enterocolitica

  2013cites this paper
• New vaccines against influenza virus

  2013cites this paper
• TLR1-induced chemokine production is critical for mucosal immunity against Yersinia enterocolitica

  2013cites this paper
• In-vivo stimulation of macaque NKT cells with αααα Galactosylceramide

  2013cites this paper
• Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.

  2013cites this paper
• Preclinical and Clinical Development of Synthetic i NKT-Cell Glycolipid Agonists as Vaccine Adjuvants

  2013cites this paper
• Chitosan and Chitosan Derivatives as Potential Adjuvants for Influenza Vaccine

  2013cites this paper
• Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.

  2012cites this paper
• Activated iNKT Cells Promote Memory CD8+ T Cell Differentiation during Viral Infection

  2012cites this paper
• The mucosal vaccine quandary: Intranasal vs. sublingual immunization against influenza

  2012cites this paper
• Boosting the immune response: the use of iNKT cell ligands as vaccine adjuvants

  2012influential citation
• Natural killer T cell based Immunotherapy.

  2012cites this paper
• Invariant NKT Cell-Based Vaccine Strategies

  2012cites this paper
• DC-Based Immunotherapy Targeting NKT Cells

  2012cites this paper
• Invariant NKT Cells: Regulation and Function during Viral Infection

  2012cites this paper
• Editorial: NKT get the ˈflu: NKT cells as (mostly) good guys in influenza; monocytic cells as double agents

  2012cites this paper
• Potential Role of Invariant NKT Cells in the Control of Pulmonary Inflammation and CD8+ T Cell Response during Acute Influenza A Virus H3N2 Pneumonia

  2011cites this paper
• of NKT Cells Eosinophilia Is Mediated through the Activation Induced Airway − -Galactosylceramide α

  2011cites this paper
• Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.

  2011cites this paper
• Chitosan Nanoparticle as a Novel Delivery System for A/H1n1 Influenza Vaccine: Safe Property and Immunogenicity in Mice

  2011cites this paper
• Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine.

  2011cites this paper
• An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.

  2011cites this paper
• α-Galactosylceramide–Induced Airway Eosinophilia Is Mediated through the Activation of NKT Cells

  2011cites this paper
• iNKT cells in microbial immunity: recognition of microbial glycolipids

  2011cites this paper
• Mucosal adjuvants and their mode of action in the female genital tract

  2010cites this paper
• The invariant NKT cell subset in anti‐viral defenses: a dark horse in anti‐influenza immunity?

  2010cites this paper
• CHARACTERIZATION OF ALPHA-GALACTOSYLCERAMIDE AS A MUCOSAL ADJUVANT

  2010cites this paper
• Needle-free influenza vaccination.

  2010cites this paper
• Contribution of guanine nucleotide binding protein beta polypeptide 3 (GNB3) and lymphocyte activation gene 3 (LAG-3) to HIV susceptibility and immune dysfunction

  2010cites this paper
• Adjuvant activity mediated by iNKT cells.

  2010cites this paper
• NKT cell immune responses to viral infection

  2009cites this paper
• NKT cells: Friend or foe during viral infections?

  2009cites this paper
• Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

  2009cites this paper
• Incorporation of NKT Cell-Activating Glycolipids Enhances Immunogenicity and Vaccine Efficacy of Mycobacterium bovis Bacillus Calmette-Guérin1

  2009cites this paper
• Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.

  2009cites this paper
• Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity

  2009cites this paper
• Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.

  2009cites this paper
• Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses

  2008cites this paper
• A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

  2008cites this paper
• Immune modulators with defined molecular targets: Cornerstone to optimize rational vaccine design

  2008cites this paper
• Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance.

  2008cites this paper
• Host immunity during RSV pathogenesis.

  2008cites this paper
• Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants

  2008cites this paper
• The role of NKT cells in tumor immunity.

  2008cites this paper
• alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors.

  2008cites this paper
• The development of stable influenza vaccine powder formulations for new needle-free dosage forms

  2007cites this paper
• Development of stable influenza vaccine powder formulations for non-parenteral dosage forms: challenges and possibilities

  2007cites this paper